H6PD Gene Polymorphisms (R453Q and D151A) and Polycystic Ovary Syndrome: A Case-Control Study in A Population of Iranian Kurdish Women

Document Type : Original Article


1 Internal Medicine Department, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Department of Anatomical Sciences, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran


Background: Polycystic ovary syndrome (PCOS) is known as the most common endocrine and metabolic disorder in the reproductive-age women. Due to the effects of PCOS on the physical and mental health, the investigation of the factors affecting the development of PCOS is crucial. Hexose-6-phosphate dehydrogenase (H6PD) is a microsomal enzyme that catalyzes the first two reactions of the oxidative chain of the pentose phosphate pathway. The present study examined the polymorphisms of the H6PD gene (R453Q and D151A) in PCOS patients of Iranian Kurdish women.
Materials and Methods: In this case-control study, a total, of 200 female volunteers in two equal groups participated in our study. The PCOS patients were selected based on the Rotterdam diagnostic criteria. The association of H6PD gene polymorphisms, D151A and R453Q, with the development of PCOS were investigated. The polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping. Statistical analysis was applied by the SPSS (version 16) software.
Results: Statistically significant lower frequencies of AA+AG genotype (37% vs. 55%, P=0.01) and A allele (22.5%
vs. 34%, P=0.01) of R453Q were observed in the patients compared to the controls. In the case of D151A, no significant
differences were observed in the frequency of genotypes and alleles between the two groups.
Conclusion: The findings of this study suggest that variants of H6PD R453Q affect the risk of PCOS.


  1. Naseri R, Barzingarosi E, Sohrabi M, Alimoradi Y, Cheraghian Fard M, Jalili C. The effect of leptin receptor gene polymorphisms (R223Q and P1019P) in susceptibility to polycystic ovarian syndrome in Kurdish women. Int J Fertil Steril. 2021; 15(2): 123-127.
  2. Legro RS. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am. 1999; 28(2): 379-396.
  3. Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord. 2007; 8(2): 127-141.
  4. Ju R, Wu W, Tang Q, Wu D, Xia Y, Wu J, et al. Association analysis between the polymorphisms of HSD11B1 and H6PD and risk of polycystic ovary syndrome in Chinese population. PLoS One. 2015; 10(10): e0140326.
  5. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015; 36(5): 487-525.
  6. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91(1): 48-53.
  7. Padmanabhan V, Veiga-Lopez A. Animal models of the polycystic ovary syndrome phenotype. Steroids. 2013; 78(8): 734-740.
  8. Qin K, Rosenfield RL. Mutations of the hexose-6-phosphatedehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome. Steroids. 2011; 76(1-2): 135-139.
  9. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet. 2003; 34(4): 434-439.
  10. Martínez-García MA, San-Millán JL, Escobar-Morreale HF. The R453Q and D151A polymorphisms of hexose-6-phosphate dehydrogenase gene (H6PD) influence the polycystic ovary syndrome (PCOS) and obesity. Gene. 2012; 497(1): 38-44.
  11. Krczal D, Ritter H, Kömpf J. Polymorphism of glucose dehydrogenase (GDH, EC formal and population genetic data. Hum Genet. 1993; 91(3): 290-292.
  12. Mason PJ, Stevens D, Diez A, Knight SW, Scopes DA, Vulliamy TJ. Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells Mol Dis. 1999; 25(1): 30-37.
  13. Hewitt KN, Walker EA, Stewart PM. Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity. Endocrinology. 2005; 146(6): 2539- 2543.
  14. Valkenburg O, Uitterlinden AG, Themmen AP, de Jong FH, Hofman A, Fauser BC, et al. Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum Reprod. 2011; 26(10): 2902-2911.
  15. San Millán JL, Botella-Carretero JI, Alvarez-Blasco F, Luque- Ramírez M, Sancho J, Moghetti P, et al. A study of the hexose-6- phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90(7): 4157-4162.
  16. Gadalla MA, Norman RJ, Tay CT, Hiam DS, Melder A, Pundir J, et al. Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: an overview of systematic reviews. Int J Fertil Steril. 2020; 13(4): 257-270.
  17. Moradi MT, Yari K, Khodarahmi R. A novel, efficient, fast and inexpensive DNA extraction protocol from whole blood applicable for studying drug-DNA interaction. J Rep Pharm Sci. 2014; 3(1): 80-84.
  18. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 2000; 85(8): 2767-2774.
  19. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril. 1999; 72(1): 21-25.
  20. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab. 2011; 96(2): E304-311.
  21. Barber TM, Golding SJ, Alvey C, Wass JA, Karpe F, Franks S, et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93(3): 999-1004.
  22. Li Y, Chen C, Ma Y, Xiao J, Luo G, Li Y, et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019; 228: 167-175.
  23. Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord. 2007; 8(4): 331-342.
  24. Rogoff D, Ryder JW, Black K, Yan Z, Burgess SC, McMillan DR, et al. Abnormalities of glucose homeostasis and the hypothalamic-pituitaryadrenal axis in mice lacking hexose-6-phosphate dehydrogenase. Endocrinology. 2007; 148(10): 5072-5080.
  25. Zhang YL, Zhong X, Gjoka Z, Li Y, Stochaj W, Stahl M, et al. H6PDH interacts directly with 11beta-HSD1: implications for determining the directionality of gluc ocorticoid catalysis. Arch Biochem Biophys. 2009; 483(1): 45-54.